Atea Pharmaceuticals AVIR Cash Flow Statement (2019-2026)

NASDAQ AVIR
$5.86 +0.03 (+0.60%)
As of: Sep 4, 2026 · 2:22 PM EDT
Reported Financials

Atea Pharmaceuticals Quarterly Cash Flow Statement

Periods 28 quarters
Latest Jun 2026

Atea Pharmaceuticals reported cash from operations of -$37.08M and free cash flow of -$37.08M for the quarter ended Jun 2026, down 12.8% year over year. This cash flow statement covers 28 quarters of results from Sep 2019 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-28.19M117.13M-42.08M-31.34M-8.07M-34.43M-35.47M-28.18M-33.14M-39.16M-63.17M-40.52M-31.15M-33.54M-34.27M-37.16M-42.05M-16.48M-45.44M-32.93M
Share-based Compensation
10.99M11.35M11.66M11.91M11.50M11.64M16.65M16.89M17.01M12.16M19.95M20.16M20.17M14.30M22.71M22.89M22.84M4.58M23.43M21.85M
Cash from Operations
22.60M-75.42M-59.01M-19.19M-21.24M-21.55M-29.85M-16.12M-17.59M-21.83M-39.87M-42.20M-23.04M-30.40M-30.56M-32.87M-40.38M-28.22M-46.39M-37.08M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles
7.93M3.09M3.70M4.32M4.34M3.49M3.02M2.60M2.71M1.74M1.32M1.07M0.81M0.58M0.54M
Depreciation & Amortization (CF)Depreciation & Amortization
0.01M0.01M0.01M0.04M0.11M0.10M0.10M0.10M0.10M0.10M0.10M0.10M0.10M0.10M0.10M0.10M0.10M0.10M0.10M0.10M
Change in Working Capital
Change in Account Payables
11.49M-17.66M-0.88M10.23M-12.77M1.43M-1.85M3.26M-3.57M3.86M16.89M-15.67M0.32M-1.33M2.93M1.46M-5.33M9.43M-3.50M0.61M
Change in Accured Expenses
9.69M10.60M-28.01M-13.57M2.48M1.49M-4.16M0.65M6.41M9.76M-7.82M1.11M-1.60M-5.12M0.35M-2.95M5.52M9.73M-2.71M-5.64M
Other Working Capital Changes
-1.36M4.74M-0.28M-2.72M7.47M1.77M-2.31M0.86M-4.57M4.16M-5.08M-3.12M-0.06M2.34M0.64M-2.38M0.94M2.33M-1.97M1.86M
Investing Activities
Capital Expenditures
0.70M1.22M0.02M
Change in Acquisitions & Divestments
91.89M181.11M199.78M146.78M75.00M224.00M131.95M106.23M55.10M208.25M116.02M56.08M90.38M104.28M68.12M
Cash from Investing Activities
-0.04M-1.88M-486.98M33.49M24.48M46.56M-58.51M27.77M56.80M124.69M-122.01M-3.37M85.61M15.29M41.30M46.59M29.74M34.31M
Financing Activities
Other financing activities
0.80M0.14M0.22M0.14M0.17M0.09M0.15M0.12M0.14M0.06M0.87M
Change in Capital Stock
Net Shares Issued and Repurchased
0.21M0.30M2.90M0.48M0.36M0.61M0.28M0.39M0.06M0.39M0.69M0.62M
Net Equity Issued and Repurchased
Misc.
Cash from Financing Activities
0.80M0.14M0.22M0.15M0.17M0.09M0.15M0.12M-0.35M-14.09M-11.30M0.26M
Change in Cash
23.40M-75.28M-58.83M-21.07M-508.07M11.94M-5.21M30.45M-76.01M5.94M17.09M82.48M-144.93M-33.77M54.70M-31.67M-10.38M18.37M-16.40M-2.77M
Free Cash Flow
22.60M-75.42M-59.71M-20.41M-21.26M-21.55M-29.85M-16.12M-17.59M-21.83M-39.87M-42.20M-23.04M-30.40M-30.56M-32.87M-40.38M-28.22M-46.39M-37.08M
Net Cash Flow
23.40M-75.28M-58.83M-21.07M-508.07M11.94M-5.21M30.45M-76.01M5.94M17.09M82.48M-144.93M-33.77M54.70M-31.67M-10.38M18.37M-16.40M-2.77M